Earnings Briefing | Pets at Home Group Plc | Stabilising finish to FY26, but retail recovery still needs harder proof

Earnings Briefing | Pets at Home Group Plc

Stabilising finish to FY26, but retail recovery still needs harder proof

Scoring: +1 ●●●●●

Impact on forecasts: FY27 underlying PBT ~0%; FY26/27 DPS -25-30%

Time saved: 20 min

No new profit warning here: FY26 underlying PBT of c£92m is a small miss versus an older 1-Mar snapshot, but likely close to live expectations. The key point is that trading did not worsen again after the autumn reset.
Retail improved, but only from the floor: H2 Retail volume and LFL turned positive, implying c£26.5m of H2 Retail PBT versus £3.5m in H1. Full-year Retail PBT is still c59% below FY25, so this is stabilisation rather than recovery proof.
Vet remains the earnings backbone: Vet PBT of c£83m is up on FY25 and now provides most of the group’s profit support. CMA commentary stayed reassuring, so the near-term debate remains retail margin rebuild.
Forecast changes skew to capital returns: Management is comfortable with FY27 consensus around £99m, but the shift to a 50% payout ratio may cut DPS forecasts materially, partly offset by larger buybacks and mild EPS support.

Financials | In line overall; Retail improved, Vet did the work

FY26 pre-close: key items versus expectations

Metric	Consensus	Actual	Beat/miss	Comments
Group underlying PBT (£m)	94.3¹	c92.0	Miss (-2.5%)	Best hard comparable line; likely closer to in line versus live numbers than this older snapshot suggests.
Retail H2 LFL	Slightly positive	Positive	Inline sign	No magnitude given; management said Q4 improved sequentially over Q3.
Retail underlying PBT (£m)	n/a	c30.0	n/a	Implies H2 c£26.5m versus H1 £3.5m.
Vet Group PBT (£m)	n/a	c83.0	n/a	Up c9% YoY versus FY25 and still the earnings anchor.
Non-underlying costs (£m)	c8.3¹	c7.0	Better	Low-confidence comparison because consensus adjustment lines did not reconcile cleanly.
Net debt (£m)	n/a	c20.0	n/a	Better than prior own guidance of c£25m after £85m returned to shareholders.

¹ Supplied consensus snapshot dated 1 Mar 2026 and likely stale versus live estimates.
All figures in £m unless otherwise stated.

Retail H2 was materially better: The c£30m full-year Retail PBT implies c£26.5m in H2, matching the statement’s positive H2 LFL, volume growth and stronger Q4.
But Retail is still far from normalised: Implied H2 Retail PBT was still roughly half FY25 H2, and full-year Retail PBT is c59% below last year. This supports a trough thesis, not a full recovery.
Vet is now carrying the group: Vet PBT of c£83m is up c9% YoY and is now the main reason group PBT held near £92m.
Cash was a touch better than feared: Year-end net debt of c£20m beat prior c£25m guidance despite £85m returned through dividends and buybacks.

Outlook | FY27 intact, but not an upgrade story

FY27 read-across: guidance and model implications

Area	Current statement	Estimate implication
FY27 underlying PBT	Comfortable with current analyst consensus; company cites £99m	Little change if models were already near £99m; older >£100m numbers may see mild pressure.
Retail exit rate	H2 volume growth, positive LFL, Q4 better than Q3	Supports a trough-year view, but still not enough detail for an upgrade case.
Energy and FX	c80% hedged	Helps reduce near-term cost volatility.
Dividend / buyback mix	Dividend rebased to 50% payout; total cash return unchanged	DPS downside risk versus legacy models, partly offset by higher buybacks.
CMA / Vet	No adverse impact expected on Vet growth ambitions	De-risks outer-year Vet assumptions more than FY27 P&L.

Consensus near £99m looks fair: A FY27 number around £99-100m only needs a c£7-8m lift from FY26. That seems plausible with completed overhead savings, pricing actions already in the base, and steady Vet performance.
Upgrade pressure still looks limited: Management offered comfort with consensus, not a numeric guide. That should calm downgrade risk, but it does not yet argue for higher numbers.
Dividend models likely need resetting: A 50% payout ratio sits below many legacy dividend assumptions. Total shareholder return is unchanged, but more of it becomes discretionary buyback.

Forecast agenda | Outer years hinge mainly on Retail margins

Independent model: where earnings may settle

Scenario	FY26E underlying PBT (£m)	FY27E underlying PBT (£m)	FY28E underlying PBT (£m)	Main driver
Bear	90	89	97	Retail margin stalls and Insurance drag persists.
Base	92	100	115	Gradual Retail recovery with steady Vet growth.
Bull	94	112	138	Faster Retail margin rebuild and better Vet momentum.

Near-term modelling edge is limited: Independent base-case FY27 underlying PBT of c£100m is essentially in line with the company-cited £99m consensus.
Retail margin drives the debate: In the model, a 50bp swing in Retail margin moves group PBT by roughly £6-7m, larger than equivalent Vet sensitivities.
Insurance still drags outer years: The pre-close ignored Insurance, but a sensible model still carries losses through FY27, with a cleaner benefit only by FY28.

What people might miss | Disclosure is lighter because proof is lacking

This was an unusually sparse update: There was no revenue table, no LFL magnitude, no transaction or customer KPIs, no digital metrics, no vet capacity data, and no Insurance commentary.
Recovery quality remains hard to test: Management highlighted positive H2 LFL and volume, but gave no numbers to judge price/mix, margin quality or customer retention.
The segment bridge still matters: Retail c£30m plus Vet c£83m versus Group c£92m implies roughly £21m of central and Insurance drag that the note did not explain.
Credibility is improving, not restored: The tone has shifted from transformation to repair, which is healthier. But repeated “benefits ahead” language means May prelims need hard evidence before the market should pay for a fuller Retail recovery.

This content is provided for general information only. It is not investment research and does not constitute advice, a recommendation, or a solicitation to trade. Primer can make mistakes - please verify independently.

Driven by AI, built by analysts.